VCYT Stock — Veracyte, Inc.

Up next

Next earnings call

Oct 26, 2026 Est · unconfirmed · in 6 wks

Latest filing: 10-Q

filed Jul 31, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$561.90M

Trailing 12 months

Net income (TTM)

$114.48M

Trailing 12 months

Revenue growth YoY

+15.5%

Year over year

Operating margin

18.8%

Trailing 12 months

P / E (TTM)

29.2

Trailing earnings · reciprocal yield 3.4%

FCF yield

5.1%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+4.7%

Year over year · more shares

Price change (1Y)

+28.3%

Trailing year

Short interest

10.0%

Latest settlement · 5.8 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Jul 30, 2026

Q2 FY26

TL;DR. Veracyte delivered Q2 revenue of $150.3M (+15% YoY) with adjusted EBITDA margin of 29.2%, launched Prosigna LDT and TrueMRD for MIBC, and raised full-year revenue guidance to $590–$596M (14–15% growth), though it trimmed Decipher volume expectations by ~1,000 tests in the low-risk setting due to NCCN guideline changes.

Bullish

+ Q2 total revenue grew 15% to $150.3M with testing revenue up 19% to $145.7M, including Decipher +20% and Affirma +18%.
+ Raised full-year 2026 total revenue guidance to $590–$596M (14–15% growth) and testing revenue to $576–$582M (17–18% growth).
+ Q2 adjusted EBITDA margin reached 29.2%, above the long-term 25%+ target, with GAAP net income of $25.5M.
+ Launched Prosigna LDT and TrueMRD for MIBC, securing first Medicare coverage for the whole-genome TrueMRD platform.
+ Generated $45.8M of cash from operations, ending with $485.2M in cash, equivalents, and short-term investments.

Bearish

− Cut Decipher full-year volume expectations by ~1,000 tests in the low-risk setting following late-2024 NCCN guideline change.
− Affirma's no-result-rate benefit of ~400 bps and strong PPCs create tougher year-over-year comps for 2027.
− Biopharmaceutical and other revenue declined to $0.8M from $4.3M YoY due to Veracyte SAS restructuring/liquidation.
− Prosigna still lacks Medicare reimbursement and its contribution is excluded from 2026 guidance.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Neutral Momentum Neutral Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Neutral

50 / 200-day cross No cross

Price vs 200-day avg −4%

below

Price vs 50-day avg −17%

below

RSI (14) 38

neutral

MACD trend Positive

52-week position 36%

mid-range

Momentum

relative strength

Neutral

1-month return −4%

trailing

6-month return +28%

trailing

YTD return −3%

this year

Relative strength +11%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $49 › 200d $43 — 50d above 200d

Institutional flow Accumulating

+10% holders QoQ · +77 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

10.05% of float · ▲ +19.0% MoM · 5.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

369 holders — near 3-yr high, broad support

Squeeze score 72

high risk · 0–100

Fundamentals

Excellent

Revenue growth +16%

Y/Y

Gross margin 70%

expanding

EPS growth +165%

Y/Y

Free cash flow $126.6M

Valuation P/E 29.2

below peers

Quant / Vol

risk profile

Very High

Volatility 64%

annualized · 1-yr

Max drawdown −39%

past year

ATR 5.2%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 3

Latest guidance · from the 8-K filed Jul 30, 2026

Total revenue · 2026 $590M – $596M

prior FY $517.15M midpoint +14.7% Y/Y

Testing revenue · 2026 $576M – $582M

Prior guidance period ended · from the 8-K filed Aug 6, 2024

Total revenue · full-year 2024 $432M – $438M

Testing revenue growth · full-year 2024 25%

Cash, cash equivalents and short-term investments · end of the year 2024 $260M – $270M

Guided vs delivered · last 3 settled

Total revenue full-year 2024

guided $432M – $438M

guided $432M – $438M $445.76M Beat +2.5%

Total revenue 2022

guided $260M – $275M

guided $260M – $275M $296.54M Beat +10.9%

Revenue 2021

guided $210M – $218M

guided $210M – $218M $219.51M Beat +2.6%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral

1 · 4 · 1

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−4% Neutral

Price vs 50-day avg

−17% Bearish

RSI (14)

38 Neutral

MACD trend

Positive Bullish

52-week position

36% Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $49 › 200d $43 — 50d above 200d

Institutional flow Accumulating

+10% holders QoQ · +77 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Rising

10.05% of float · ▲ +19.0% MoM · 5.8 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

369 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $30 Now $41 · 36% Range high $60

vs 200-day avg -4% vs 50-day avg -17%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Diagnostics & Research — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
VCYT Veracyte, Inc. this stock	$3.29B	-2.9%	+16.0%	29.2	10.0%
TMO Thermo Fisher Scientific Inc.	$225.48B	+5.2%	+14.5%	32.8	1.5%
DHR Danaher Corp /De/	$140.70B	-12.6%	+8.5%	35.5	1.4%
NTRA Natera, Inc.	$47.41B	+43.6%	-2.8%	—	3.8%
IQV Iqvia Holdings Inc.	$43.69B	+16.1%	+41.6%	32.5	2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

369

% held: 110.9%
Net QoQ: +661.9K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

361

View

Short & Settlement

Short Interest Rising

Shares short

8.1M

Days to cover: 5.8d
Change: +1.3M sh

View

Short Volume

Short vol %

68%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

24.4K

Value: $1.1M
As of: Aug 5, 2026

View

Off-Exchange

Off-exchange %

42.3%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Congressional Trades Buy

Member

Gilbert Cisneros

Amount: $1.0K–$15.0K
Traded: Mar 3, 2026

View

Financials

Revenue (FY)

$517.1M

Net income (FY): $66.4M
EPS diluted: $0.82

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Aug 11, 2026
This year: 13

View

Proposed Sales

Value

$163.1K

Shares: 3.7K
Filed: Sep 4, 2026

View

Earnings & Events

Earnings Calls Upcoming

Next call

Sep 15, 2026

Last call: Aug 11, 2026

View

Investor Relations

Upcoming events

1

View

	5D	20D	120D	MTD	YTD
VCYT	-8.5%	-4.1%	+28.4%	-5.4%	-2.9%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-7.4%	-2.3%	+10.5%	-5.0%	-15.0%

VCYT · Veracyte, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance